NCT03099382View on ClinicalTrials.gov

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

457

Participants

Timeline

Start Date

May 5, 2017

Primary Completion Date

May 6, 2019

Study Completion Date

May 6, 2019

Conditions
Esophageal Carcinoma
Interventions
BIOLOGICAL

camrelizumab

Subjects receive camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks

DRUG

Docetaxel

Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks

DRUG

Irinotecan

Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks

Trial Locations (2)

Unknown

307 Hospital of PLA, Beijing

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03099382 - Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer | Biotech Hunter | Biotech Hunter